Advanced Glycation End Products and Inflammation in Type 1 Diabetes Development
Type 1 diabetes (T1D) is an autoimmune disease in which the β-cells of the pancreas are attacked by the host’s immune system, ultimately resulting in hyperglycemia. It is a complex multifactorial disease postulated to result from a combination of genetic and environmental factors. In parallel with i...
Main Authors: | Chenping Du, Rani O. Whiddett, Irina Buckle, Chen Chen, Josephine M. Forbes, Amelia K. Fotheringham |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-11-01
|
Series: | Cells |
Subjects: | |
Online Access: | https://www.mdpi.com/2073-4409/11/21/3503 |
Similar Items
-
Association between Advanced Glycation End-Products and Sarcopenia in Patients with Chronic Kidney Disease
by: Paolo Molinari, et al.
Published: (2022-06-01) -
In Patients with Chronic Kidney Disease Advanced Glycation End-Products Receptors Isoforms (sRAGE and esRAGE) Are Associated with Malnutrition
by: Lara Caldiroli, et al.
Published: (2022-06-01) -
Advanced glycation end products in diabetic retinopathy and phytochemical therapy
by: Qingzheng Kang, et al.
Published: (2022-11-01) -
Role of Advanced Glycation End-Products and Oxidative Stress in Type-2-Diabetes-Induced Bone Fragility and Implications on Fracture Risk Stratification
by: Guido Cavati, et al.
Published: (2023-04-01) -
Advanced glycation end products regulate the receptor of AGEs epigenetically
by: Xiaoqing Wu, et al.
Published: (2023-02-01)